Keywords
How to Cite
Abstract
Lung cancer (LC) is a common malignant neoplasm (MN) with high lethality, often detected at late stages. The implementation of lung cancer screening can change the ratio in favor of the early stages. Screening could help diagnose early-stage LC in 60% of patients. Multiple primary LCs occur in 4–10% of patients within five years after treatment. The presence of oligo-metastatic disease only in the lungs (up to 5 nodules) occurs in 6-40% of patients with malignant tumors, and complete resection could increase 5-year survival to 20-40%. Due to functional limitations, surgical treatment can be performed only in 65-70% of patients. Stereotactic radiation therapy gives an opportunity to accurately deliver a high dose of radiation to the tumor with minimal damage to the surrounding healthy tissues. Local control is possible in 85–95% of cases, and 3-year overall survival is about 60–80%. New algorithms for fractionation and dose determination (BED10 ≥ 100 Gy) could improve the treatment results for early-stage lung cancer and oligometastatic lesions. In this non-systematic review, we analyze a recent publication and our own experience. We consider the effectiveness and safety of stereotactic radiotherapy and planning, modeling, fractionation, dose restrictions on critical organs, radiation reactions, and adverse events. We conclude that randomized controlled trials can reveal the stereotactic radiation therapy's potential in patients with primary and oligo-metastatic pulmonary tumors.
References
Антипов Ф.Е., Канаев С.В., Новиков С.Н. и соавт. Моделирование синхронизации дыхания при проведении стереотаксической лучевой терапии опухолевых очагов в легких // В книге: Сборник научных работ V Петербургского Международного онкологического форума «Белые ночи 2019» 20–23.06.2019 г. СПб. АННМО «Вопросы онкологии». 2019:98–100.
Арсеньев А.И., Новиков С.Н., Канаев С.В. и соавт. Стереотаксическая лучевая терапия в лечении ранних форм немелкоклеточного рака лёгкого // Вопросы онкологии. 2018;64(5):638–644.
Смоленов Е.И., Рагулин Ю.А., Пикин О.В. Классификация легочных метастазов: возможности применения в клинической // Сибирский онкологический журнал. 2018;17(2):34–40. https://doi.org:10.21294/1814-4861-2018-17-2-34-40.
Зозуля А.Ю., Новиков С.Н., Балдуева И.А. и др. Изменение иммунного статуса у пациентов солидными опухолями на фоне стереотаксической лучевой терапии // Вопр. онкологии. 2020;66(3):277–282.
Arifin A.J., Al-Shafa F., Chen H. et al. Is lung stereotactic ablative radiotherapy safe after pneumonectomy? — a systematic review // Transl. Lung Cancer Res. 2020;9(2):348–353. https://doi:10.21037/tlcr.2020.01.18.
Baumann P., Nyman J., Hoyer M., Weinberg B. Outcome in aprospective phase II trial of medically inoperable stage I nonsmall-cell lung cancer patients treated with stereotactic body radiotherapy // J. Clin. Oncol. 2009;27(20):3290–3296.
Bogart J.A., Hodgson L., Seagren S.L., Blackstock A.W. Phase Istudy of accelerated conformal radiotherapy for stage I nonsmall-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904 // J. Clin. Oncol. 2010;28(2):202–206.
Chen H., Laba J.M., Zayed S. et al. Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review // J. Thorac. Oncol. 2019;14(8):1332–1342. https://doi:10.1016/j.jtho.2019.04.018.
Crabtree T.D., Denlinger C.E., Meyers B.F., El Naga I. Stereotactic body radiotherapy versus surgical resection for stage I non-small cell lung cancer // J. Thorac. Cardiovasc Surg. 2010;140(2):377–386.
Ernst-Stecken A., Lambrecht U., Mueller R. et al. Hypofractionated stereotactic radiotherapy for primary and secondary intrapulmonary tumors: first results of a phase I/II study // Strahlenther. Onkol. 2006;182:696–702.
Farikis A.J., McGarry R.C., Yiannoutsos C.T., Papiez L. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study // Int. J. Radiat. Oncol. Biol. Phys. 2009;75(3):677–682.
Feddock J., Arnold S.M., Shelton B.J., Sinha P. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study // Int. J. Radiat. Oncol. Biol. Phys. 2013;85(5):1325–1331.
Formenti S.C., Demaria S. Systemic effects of local radiotherapy // Lancet Oncol. 2009;10(7):718–726.
Guckenberger M., Lievens Y., Bouma A.B. et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation // Lancet Oncol. 2020;21(1):18–28. https://doi:10.1016/S1470-2045(19)30718-1.
Guerrero M., Li X.A. Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy // Phys. Med. Biol. 2004;49:4825–4835. https://doi:10.1088/0031-9155/49/20/012.
Karam S.D., Horne Z.D., Hong R.L., McRae D. Dose escalationwith stereotactic body radiation therapy boost for locally advanced non small cell lung cancer // Radiat. Oncol. 2013;8:179.
Kelly P., Balter P.A., Rebueno N., Sharp H.J. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation // University of California. 2010;78(5):1387–1393.
Le Q.T., Loo B.W., Ho A., Cotrutz C. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors // J. Thorac. Oncol. 2006;1:802–809.
Liu H., Zhang X., Vinogradskiy Y.Y., Swisher S.G. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy // Int. J. Radiat. Oncol. Biol. Phys. 2012;84:1017–1023.
Nagata Y., Hiroka M., Shibata T. et al. Stereotactic body radiation therapy for T1N0M0 non-small cell lung cancer: first report for inoperable population of a phase II trial by Japan Clinical Oncology Group (JCOG 0403) // Int. J. Radiat. Oncol. Biol. Phys. 2012;84(3):46.
Palma D.A., Chen H., Bahig H. et al. Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ИЗЛ): study protocol for a phase II trial // BMC Cancer. 2019;19(1):1206. https://doi:10.1186/s12885-019-6392-8.
Park C., Papiez L., Zhang S. et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy // Int. J. Radiat. Oncol. Biol. Phys. 2008;70:847–852. https://doi:10.1016/j.ijrobp.2007.10.059.
Peulen H., Mantel F., Guckenberger M. et al. Validation of high-risk computed tomography features for detection of local recurrence after stereotactic body radiation therapy for early-stage non-small cell lung cancer // Int. J. Radiat. Oncol. Biol. Phys. 2016;96(1):134–141.
Qiu B., Aili A., Xue L. et al. Advances in Radiobiology of Stereotactic Ablative Radiotherapy // Front Oncol. 2020;10:1165. https://doi:10.3389/fonc.2020.01165.
Ronden M.I., Palma D., Slotman B.J., Senan S. Report on Radiological Changes following Stereotactic Ablative Radiotherapy (SABR) for Early-Stage Lung Tumors: A Pictorial Essay // Journal of Thoracic Oncology. 2018;13(6):855–862.
Reyngold M., Wu A., McLane A. et al. Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiotherapy (SBRT) // Radiat. Oncol. 2013;8:99.
Rusthoven K.E., Kavanagh B.D., Burri S.H. et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases // J. Clin. Oncol. 2009;27:1579–1584.
Senthi R.A., Barani I.J., Larson D.A., Roach M. Handbook of Evidence-Based Stereotactic Radiosurgery and Stereotactic Body Radiotherapy. Springer. 2016.
Shirvani S.M., Jiang J., Chang J.Y. et al. Sublobar Resection, and Stereotactic Radiation for Early-Stage Non-Small Cell Lung Cancers in the Elderly // JAMA Surg. 2014;149(12):1244–1253.
Tekati H., Spoelstra F.O.B., Palacios M. et al. Stereotactic ablative radiotherapy (SABR) for early-stage central lung tumors: New insights and approaches // Lung Cancer. 2018;23:142–148. https://www.ogc.nl/flipbook/h.tekatli.
Timmerman R., McGarry R., Yiannoutsos C. et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early stage lung cancer // J. Clin. Oncol. 2006;24(30):4833–4839.
Timmerman R., Paulus R., Galvin J. et al. Stereotactic body radiation therapy for inoperable early stage lung cancer // JAMA. 2010;303(11):1070–1076.
Tjong M.C., Malik N.H., Chen H. et al. Stereotactic ablative radiotherapy for malignant mediastinal and hilar lymphadenopathy: a systematic review // J. Thorac. Dis. 2020;12(5):2280–2287. https://doi:10.21037/jtd.2020.03.112.
Wang J.Z., Huang Z., Lo S.S. et al. A generalized linear-quadratic model for radiosurgery, stereotactic body radiation therapy, and high-dose rate brachytherapy // Sci. Transl. Med. 2010;2:39–48. https://doi:10.1126/scitranslmed.3000864.
Weichselbaum R.R., Hellman S. Oligometastases revisited // Nat. Rev. Clin. Oncol. 2011;8 (6):378–382. https://doi:10.1038/nrclinonc.2011.44
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021